Board member and chairman of the board
Read more
Board member and Chairman of the Board since 2026.
Education and experience: MSc in Engineering Physics from Chalmers University of Technology and MBA from INSEAD. Per Aniansson brings more than 25 years of experience from venture capital, investments, board work and operational leadership roles within life sciences, medtech, deeptech and software companies, both public and private. During his career, Per has held leadership roles including Investment Director and CFO at KD Ventures, a public Life Science Investment Company, and has worked with venture capital and investment firms such as Fouriertransform, InnovationsKapital, Industrivärden and Siemens. Earlier in his career, he worked with strategy and management consulting at Accenture and Arthur D. Little, primarily focused on the pharmaceutical and medtech sectors. He has also served as CEO of two UK-based medtech companies and has participated in several successful IPOs and scale-up journeys.
Other current roles: Chairman of Abarceo Pharma, Colorifix, Turnpike Group, and board member of AAC Clyde Space.
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
Per Aniansson is independent in relation to the company and its management, as well as in relation to major shareholders.
Board member
Read more
Board member since 2022.
Education and experience: MBA in Finance and Business Management from Stern School of Business at New York University, BS in Business Administration from Questrom School of Business at Boston University, provides the board with more than 20 years of expertise and experience in the healthcare industry with extensive knowledge in spine, orthobiologics and neuromodulation. Jill has a direct experience in global medical device commercialization, launching innovative technologies, strategic marketing, healthcare consumerism and patient care pathway modeling. During her career, Jill has held leadership roles with major healthcare companies such as Johnson & Johnson and Baxter, as well as serving as an executive at high-growth, innovative companies such as AxoGen (US Nasdaq: AXGN) and ApaTech (UK), a company she helped divest to Baxter and Avation Medical.
Other current roles: CEO and Board Member Avation Medical, Board Member InteloMed, Inc.
Holdings in OssDsign: 85 611 shares and 97 659 subscription options.
Jill Schiaparelli is independent in relation to the company and its management, as well as in relation to major shareholders.
Board member
Read more
Board member since 2024.
Education and experience: Christer Fåhraeus has thirty years of experience as CEO, board member, and chairman from fast-growing listed and unlisted companies in Life Science and Tech. He is also the founder of companies such as CellaVision AB, FlatFrog Laboratories AB, EQL Pharma AB, Anoto Group AB, Precise Biometrics AB, and Fåhraeus Startup and Growth AB. He has accumulated more than 200 years of combined board experience from listed and unlisted companies.
Medical Candidate and Ph.D. in Neurophysiology from the Faculty of Medicine at Lund University, Master of Science in Medical Engineering from the University of California San Diego (USA), and equivalent to five years of full-time studies in Mathematics and Physics at Lund University and LTH (Engineering Physics). Graduate of the Swedish Armed Forces Interpreter Academy and holds an honorary Doctorate of Technology from Lund University of Technology.
Founder of EQL Pharma AB. Chief Executive Officer 2006 – 2022, thereafter Chairman (2022 -). Board member since 2006. Chairman of the Remuneration Committee.
Other current roles: Chairman of FSG Fund II AB, Fåhraeus Startup & Growth AB, and ApoEco Sverige AB. Board member of Airsonett AB, CellaVision AB, Checkin.com Group AB, FlatFrog Laboratories AB, Melius Pharma AB, and Bionamic AB.
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
Christer Fåhraeus is independent in relation to the company and its management, as well as in relation to major shareholders.
Board member
Read more
Board member since 2025.
Education and experience: Master's degree in biomedical engineering and 2 years of economics studies. Previously worked as a management consultant in the healthcare sector in Switzerland and Sweden and as CEO in several medium-sized companies in the healthcare sector.
Other current roles: CEO of Alumbra Group AB, board member of MedCap AB (publ) and chairman of Bioswed Scientific AB.
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
David Jern is independent in relation to the company and its management, as well as in relation to major shareholders.
Board member
Read more
Board member since 2025.
Education and experience: Tomas Blomquist has over 30 years of international experience in the healthcare sector. He has held executive roles at global companies such as Abbott, Roche, Johnson & Johnson, and Analyticon Biotechnologies. Tomas served as CEO and President of Biotage AB from 2019 until January 2024. He has also served on management teams and boards at several international companies and has extensive expertise in corporate strategy, vision, and culture, team and leadership development. He holds an education from the Stockholm School of Economics.
Other assignments: Tomas is a board member of Nolato AB (since May 2021).
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
Tomas Blomquist is independent in relation to the company and its management, as well as in relation to major shareholders.
